Hospitalization For Congestive Heart Failure Research Articles

Takayasu Arteritis Manifesting as Acute Kidney Injury and Congestion Due to Renal-Artery Stenosis and Myocarditis: A Case Report

Abstract Background Takayasu arteritis is a large vessel vasculitis that affects the aorta and its primary branches. Myocarditis is a rare life-threatening complication and potential diagnostic pitfall in patients with Takayasu arteritis. Case Summary A previously healthy 18-year-old woman presenting with fever, back pain, and dyspnea was admitted to another hospital for acute hypertension (blood pressure, 230/106 mmHg) and congestive heart failure. Intravenous methylprednisolone pulse with antihypertensive and diuretic medications slightly improved her congestion. However, she developed acute kidney injury and was transferred to our hospital. Transthoracic echocardiography indicated a left ventricular ejection fraction of 45% and diffuse left ventricular hypokinesis. Doppler ultrasound test and magnetic resonance angiography revealed severe bilateral renal-artery stenosis. Her diagnosis was Takayasu arteritis and she received high-dose glucocorticoids. She required temporary hemodialysis, but two months after admission, her serum creatinine improved to 1.1 mg/dL without surgical/cardiovascular interventions. Although the pre-discharge test with 1.5- Tesla cardiac magnetic resonance initially failed to diagnose myocarditis, 3-Tesla cardiac magnetic resonance imaging revealed increased native T1 values on T1 mapping (1283–1393 ms), moderate pericardial effusion, and systolic left ventricular wall motion abnormality, indicating active myocarditis. During 6-month subcutaneous tocilizumab treatment (162 mg/week), a left ventricular ejection fraction improved to 55–60% without a relapse. Discussion This case report highlights the benefits of early multimodal imaging tests including cardiac magnetic resonance imaging for myocarditis and renal artery involvement in Takayasu arteritis. Tocilizumab might be an efficient therapeutic option for severe acute manifestations including myocarditis in young women of reproductive age.

Impact of chronic kidney disease and end-stage renal disease on the mid-term adverse outcomes in diabetic patients with cardiovascular diseases

The evidence for the impact of renal dysfunction in patients with diabetes mellitus (DM) and first cardiovascular diseases on mid-term adverse outcomes remain scarce. This study included the data of patients with DM having first atherosclerotic cardiovascular disease (ASCVD) or congestive heart failure (CHF) from the Taipei Medical University Clinical Research Database. A Cox proportional hazards regression model was used to assess the impact of chronic kidney disease (CKD) or end-stage renal disease (ESRD) on the 1-year mortality and recurrent ASCVD/CHF outcomes. We enrolled 21,320 patients with DM hospitalized for ASCVD or CHF; of them, 18,185, 2639, and 496 were assigned to the non-CKD, CKD, and ESRD groups, respectively. After propensity score matching, compared with the non-CKD group, the CKD and ESRD groups had higher mid-term all-cause mortality (adjusted hazard ratio 1.72 [95% confidence interval 1.48–1.99] and 2.77 [2.05–3.73], respectively), cardiovascular death (1.84 [1.44–2.35] and 1.87 [1.08–3.24], respectively), and recurrent hospitalization for ASCVD (1.44 [1.24–1.68] and 2.33 [1.69–3.23], respectively) and CHF (2.08 [1.75–2.47] and 1.50 [1.04–2.17], respectively). The advancing age was associated with mortality in CKD/ESRD groups. In CKD group, male sex was associated with all-cause mortality and recurrent ASCVD risk; the diuretics usage was associated with mortality and recurrent CHF risks. Our findings suggest that CKD and ESRD are significant risk factors for mid-term adverse outcomes in patients with DM and established cardiovascular diseases. Additionally, old age, male sex and diuretics usage requires attention. Further good quality studies are needed in the future.

Impact of chronic kidney disease and end-stage renal disease on the mid-term adverse outcomes in diabetic patients with cardiovascular diseases

The evidence for the impact of renal dysfunction in patients with diabetes mellitus (DM) and first cardiovascular diseases on mid-term adverse outcomes remain scarce. This study included the data of patients with DM having first atherosclerotic cardiovascular disease (ASCVD) or congestive heart failure (CHF) from the Taipei Medical University Clinical Research Database. A Cox proportional hazards regression model was used to assess the impact of chronic kidney disease (CKD) or end-stage renal disease (ESRD) on the 1-year mortality and recurrent ASCVD/CHF outcomes. We enrolled 21,320 patients with DM hospitalized for ASCVD or CHF; of them, 18,185, 2639, and 496 were assigned to the non-CKD, CKD, and ESRD groups, respectively. After propensity score matching, compared with the non-CKD group, the CKD and ESRD groups had higher mid-term all-cause mortality (adjusted hazard ratio 1.72 [95% confidence interval 1.48–1.99] and 2.77 [2.05–3.73], respectively), cardiovascular death (1.84 [1.44–2.35] and 1.87 [1.08–3.24], respectively), and recurrent hospitalization for ASCVD (1.44 [1.24–1.68] and 2.33 [1.69–3.23], respectively) and CHF (2.08 [1.75–2.47] and 1.50 [1.04–2.17], respectively). The advancing age was associated with mortality in CKD/ESRD groups. In CKD group, male sex was associated with all-cause mortality and recurrent ASCVD risk; the diuretics usage was associated with mortality and recurrent CHF risks. Our findings suggest that CKD and ESRD are significant risk factors for mid-term adverse outcomes in patients with DM and established cardiovascular diseases. Additionally, old age, male sex and diuretics usage requires attention. Further good quality studies are needed in the future.

Heart failure: the grim reaper of the cardio-renal-metabolic triad.

Current understanding of the prognosis for patients with chronic kidney disease (CKD) and overlapping cardio-renal-metabolic components, specifically heart failure (HF) and diabetes mellitus (DM), remains limited. While previous studies have explored the interactions between CKD, HF, and DM, they have predominantly focused on cohorts of HF or DM patients. This study aims to fill this gap by investigating the long-term outcomes and treatment patterns in a cohort of CKD patients, particularly those with coexisting HF and DM. We analysed data from the Swedish national CKD patient cohort, the Swedish Renal Registry, with a follow-up period extending up to 10years. The study examined the risks of all-cause mortality, major adverse cardiovascular events (MACE)-defined as a composite of non-fatal myocardial infarction, hospitalization for congestive HF, non-fatal stroke, or cardiovascular death-and the initiation of kidney replacement therapy (KRT). Analyses were conducted using Cox proportional hazards and competing risk models. Among the 27647 patients, 48% had CKD alone, 12% had CKD with HF, 27% had CKD with DM, and 13% had CKD with both HF and DM. After 5years, mortality rates were 23% for patients with CKD, 30% for those with CKD/DM, 54% for CKD/HF, and 55% for CKD/HF/DM. The 10year absolute risk of MACE was 28% for CKD alone, 35% for CKD/DM, 67% for CKD/HF, and 73% for CKD/HF/DM. The adjusted hazard ratio (HR) for mortality was approximately three times higher in patients with any HF combination, with HRs of 2.57 [95% confidence interval (CI) 2.43-2.71] for CKD/HF and 3.22 (95% CI 3.05-3.39) for CKD/HF/DM, compared with CKD alone. The impact of HF on MACE prognosis was even more pronounced, with adjusted sub-hazard ratios (SHRs) of 3.33 (95% CI 3.14-3.53) for CKD/HF and 4.26 (95% CI 4.04-4.50) for CKD/HF/DM. Additionally, CKD patients diagnosed with HF were less likely to commence KRT, and the risk of death prior to KRT initiation was roughly twice as high for these groups, with SHRs of 2.05 (95% CI 1.93-2.18) for CKD+HF and 2.43 (95% CI 2.29-2.58) for CKD+HF+DM. In a cohort of CKD patients, having HF contributes substantially to increased mortality and the risk of MACE, and these patients are less likely to start KRT. These findings highlight the urgent need for targeted therapeutic strategies and management plans for CKD patients, particularly those with concurrent HF, to enhance patient prognosis.

Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Clinical Guideline From the American College of Physicians.

The American College of Physicians (ACP) developed this clinical guideline to update recommendations on newer pharmacologic treatments of type 2 diabetes. This clinical guideline is based on the best available evidence for effectiveness, comparative benefits and harms, consideration of patients' values and preferences, and costs. This clinical guideline is based on a systematic review of the effectiveness and harms of newer pharmacologic treatments of type 2 diabetes, including glucagon-like peptide-1 (GLP-1) agonists, a GLP-1 agonist and glucose-dependent insulinotropic polypeptide agonist, sodium-glucose cotransporter-2 (SGLT-2) inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, and long-acting insulins, used either as monotherapy or in combination with other medications. The Clinical Guidelines Committee prioritized the following outcomes, which were evaluated using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach: all-cause mortality, major adverse cardiovascular events, myocardial infarction, stroke, hospitalization for congestive heart failure, progression of chronic kidney disease, serious adverse events, and severe hypoglycemia. Weight loss, as measured by percentage of participants who achieved at least 10% total body weight loss, was a prioritized outcome, but data were insufficient for network meta-analysis and were not rated with GRADE. The audience for this clinical guideline is physicians and other clinicians. The population is nonpregnant adults with type 2 diabetes. ACP recommends adding a sodium-glucose cotransporter-2 (SGLT-2) inhibitor or glucagon-like peptide-1 (GLP-1) agonist to metformin and lifestyle modifications in adults with type 2 diabetes and inadequate glycemic control (strong recommendation; high-certainty evidence). • Use an SGLT-2 inhibitor to reduce the risk for all-cause mortality, major adverse cardiovascular events, progression of chronic kidney disease, and hospitalization due to congestive heart failure. • Use a GLP-1 agonist to reduce the risk for all-cause mortality, major adverse cardiovascular events, and stroke. ACP recommends against adding a dipeptidyl peptidase-4 (DPP-4) inhibitor to metformin and lifestyle modifications in adults with type 2 diabetes and inadequate glycemic control to reduce morbidity and all-cause mortality (strong recommendation; high-certainty evidence).

Association of Impaired Left Ventricular Mitral Filling from 4D Flow Cardiac MRI and Prognosis of Hypertrophic Cardiomyopathy.

Purpose To investigate whether the peak early filling rate normalized to the filling volume (PEFR/FV) estimated from four-dimensional (4D) flow cardiac MRI may be used to assess impaired left ventricular (LV) filling and predict clinical outcomes in individuals with hypertrophic cardiomyopathy (HCM). Materials and Methods Cardiac MRI with a 4D flow sequence and late gadolinium enhancement (LGE), as well as echocardiography, was performed in 88 individuals: 44 participants with HCM from a French prospective registry (ClinicalTrials.gov; NCT01091480) and 44 healthy volunteers matched for age and sex. In participants with HCM, a composite primary end point was assessed at follow-up, including unexplained syncope, new-onset atrial fibrillation, hospitalization for congestive heart failure, ischemic stroke, sustained ventricular arrhythmia, septal reduction therapy, and cardiac death. A Cox proportional hazard model was used to analyze associations with the primary end point. Results PEFR/FV was significantly lower in the HCM group (mean age, 51.8 years ± 18.5 [SD]; 29 male participants) compared with healthy volunteers (mean, 3.35 sec-1 ± 0.99 [0.90-5.20] vs 4.42 sec-1 ± 1.68 [2.74-11.86]; P < .001) and correlated with both B-type natriuretic peptide (BNP) level (r = -0.31; P < .001) and the ratio of pulsed Doppler early transmitral inflow to Doppler tissue imaging annulus velocities (E/E'; r = -0.54; P < .001). At a median follow-up of 2.3 years (IQR, 1.7-3.3 years), the primary end point occurred in 14 (32%) participants. A PEFR/FV of 2.61 sec-1 or less was significantly associated with occurrence of the primary end point (hazard ratio, 9.46 [95% CI: 2.61, 45.17; P < .001] to 15.21 [95% CI: 3.51, 80.22; P < .001]), independently of age, BNP level, E/E', LGE extent, and LV and left atrial strain according to successive bivariate models. Conclusion In HCM, LV filling evaluated with 4D flow cardiac MRI correlated with Doppler and biologic indexes of diastolic dysfunction and predicted clinical outcomes. Keywords: Diastolic Function, Left Ventricular Filling, Hypertrophic Cardiomyopathy, Cardiac MRI, 4D Flow Sequence Clinical trial registration no. NCT01091480 Supplemental material is available for this article. © RSNA, 2024.

Predictive Value of Artificial Intelligence-Enabled Electrocardiography in Patients With Takotsubo Cardiomyopathy.

Recent studies have indicated high rates of future major adverse cardiovascular events in patients with Takotsubo cardiomyopathy (TC), but there is no well-established tool for risk stratification. This study sought to evaluate the prognostic value of several artificial intelligence-augmented ECG (AI-ECG) algorithms in patients with TC. This study examined consecutive patients in the prospective and observational Mayo Clinic Takotsubo syndrome registry. Several previously validated AI-ECG algorithms were used for the estimation of ECG- age, probability of low ejection fraction, and probability of atrial fibrillation. Multivariable models were constructed to evaluate the association of AI-ECG and other clinical characteristics with major adverse cardiac events, defined as cardiovascular death, recurrence of TC, nonfatal myocardial infarction, hospitalization for congestive heart failure, and stroke. In the final analysis, 305 patients with TC were studied over a median follow-up of 4.8 years. Patients with future major adverse cardiac events were more likely to be older, have a history of hypertension, congestive heart failure, worse renal function, as well as high-risk AI-ECG findings compared with those without. Multivariable Cox proportional hazards analysis indicated that the presence of 2 or 3 high-risk findings detected by AI-ECG remained a significant predictor of major adverse cardiac events in patients with TC after adjustment by conventional risk factors (hazard ratio, 4.419 [95% CI, 1.833-10.66], P=0.001). The combined use of AI-ECG algorithms derived from a single 12-lead ECG might detect subtle underlying patterns associated with worse outcomes in patients with TC. This approach might be beneficial for stratifying high-risk patients with TC.

Cardiac effects of deferasirox in transfusion-dependent patients with myelodysplastic syndromes: TELESTO study.

Iron overload from repeated transfusions has a negative impact on cardiac function, and iron chelation therapy may help prevent cardiac dysfunction in transfusion-dependent patients with myelodysplastic syndromes (MDS). TELESTO (NCT00940602) was a prospective, placebo-controlled, randomised study to evaluate the iron chelator deferasirox in patients with low- or intermediate-1-risk MDS and iron overload. Echocardiographic parameters were collected at screening and during treatment. Patients receiving deferasirox experienced a significant decrease in the composite risk of hospitalisation for congestive heart failure (CHF) or worsening of cardiac function (HR = 0.23; 95% CI: 0.05, 0.99; nominal p = 0.0322) versus placebo. No significant differences between the arms were found in left ventricular ejection fraction, ventricular diameter and mass or pulmonary artery pressure. The absolute number of events was low, but the enrolled patients were younger than average for patients with MDS, with no serious cardiac comorbidities and a modest cardiovascular risk profile. These results support the effectiveness of deferasirox in preventing cardiac damage caused by iron overload in this patient population. Identification of patients developing CHF is challenging due to the lack of distinctive echocardiographic features. The treatment of iron overload may be important to prevent cardiac dysfunction in these patients, even those with moderate CHF risk.

Comparison of brain imaging and physical health between research and clinical neuroimaging cohorts of ageing.

To compare brain MRI measures between Adult Changes in Thought (ACT) participants who underwent research, clinical, or both MRI scans, and clinical health measures across the groups and non-MRI subjects. Retrospective cohort study leveraging MRI, clinical, demographic, and medication data from ACT. Three neuroradiologists reviewed MRI scans using NIH Neuroimaging Common Data Elements (CDEs). Total brain and white matter hyperintensity (WMH) volumes, clinical characteristics, and outcome measures of brain and overall health were compared between groups. 1166 MRIs were included (77 research, 1043 clinical, and 46 both) and an additional 3146 participants with no MRI were compared. Compared to the group with research MRI only, the clinical MRI group had higher prevalence of the following: acute infarcts, chronic haematoma, subarachnoid haemorrhage, subdural haemorrhage, haemorrhagic transformation, and hydrocephalus (each P < .001). Quantitative WMH burden was significantly lower (P < .001) and total brain volume significantly higher (P < .001) in research MRI participants compared to other MRI groups. Prevalence of hypertension, self-reported cerebrovascular disease, congestive heart failure, dementia, and recent hospitalization (all P < .001) and diabetes (P = .002) differed significantly across groups, with smaller proportions in the research MRI group. In ageing populations, significant differences were observed in MRI metrics between research MRI and clinical MRI groups, and clinical health metric differences between research MRI, clinical MRI, and no-MRI groups. This questions whether research cohorts can adequately represent the greater ageing population undergoing imaging. These findings may also be useful to radiologists when interpreting neuroimaging of ageing.

Impact of Myocardial Viability on Long-term Outcomes after Surgical Revascularization.

This study was conducted to evaluate whether myocardial viability assessed with cardiac magnetic resonance (CMR) affected long-term clinical outcomes after coronary artery bypass grafting (CABG) in patients with ischemic cardiomyopathy (ICMP). Preoperative CMR with late gadolinium enhancement (LGE) was performed in 103 patients (64.9 ± 10.1 years, male:female = 82:21) with 3-vessel disease and left ventricular dysfunction (ejection fraction ≤ 0.35). Transmural extent of LGE was evaluated on a 16-segment model, and transmurality was graded on a 5-point scale: grades-0, absence; 1, 1 to 25%; 2, 26 to 50%; 3, 51 to 75%; 4, 76 to 100%. Median follow-up duration was 65.5 months (interquartile range = 27.5-95.3 months). Primary endpoint was the composite of all-cause mortality or hospitalization for congestive heart failure. Operative mortality was 1.9%. During the follow-up, all-cause mortality and readmission for congestive heart failure occurred in 29 and 8 patients, respectively. The cumulative incidence of the primary endpoint was 31.3 and 46.8% at 5 and 10 years, respectively. Multivariable analysis demonstrated that the number of segments with LGE grade 4 was a significant risk factor (hazard ratio 1.42, 95% confidence interval 1.10-1.83, p = 0.007) for the primary endpoint among the variables assessed by CMR. Other risk factors included age, dialysis, chronic obstructive pulmonary disease, and EuroSCORE II. The number of myocardial segments with transmurality of LGE >75% might be a prognostic factor associated with the composite of all-cause mortality or hospitalization for congestive heart failure after CABG in patients with 3-vessel disease and ICMP.

Impact of mental disorders on unplanned readmissions for congestive heart failure patients: a population-level study.

Reducing preventable hospitalization for congestive heart failure (CHF) patients is a challenge for health systems worldwide. CHF patients who also have a recent or ongoing mental disorder may have worse health outcomes compared with CHF patients with no mental disorders. This study examined the impact of mental disorders on 28day unplanned readmissions of CHF patients. This retrospective cohort study used population-level linked public and private hospitalization and death data of adults aged ≥18years who had a CHF admission in New South Wales, Australia, between 1 January 2014 and 31 December 2020. Individuals' mental disorder diagnosis and Charlson comorbidity and hospital frailty index scores were derived from admission records. Competing risk and cause-specific risk analyses were conducted to examine the impact of having a mental disorder diagnosis on all-cause hospital readmission. Of the 65861 adults with index CHF admission discharged alive (mean age: 78.6±12.1; 48% female), 19.2% (12675) had at least one unplanned readmission within 28days following discharge. Adults with CHF with a mental disorder diagnosis within 12months had a higher risk of 28day all-cause unplanned readmission [hazard ratio (HR): 1.21, 95% confidence interval (CI): 1.15-1.27, P-value<0.001], particularly those with anxiety disorder (HR: 1.49, 95% CI: 1.35-1.65, P-value<0.001). CHF patients aged ≥85years (HR: 1.19, 95% CI: 1.11-1.28), having ≥3 other comorbidities (HR: 1.35, 95% CI: 1.25-1.46), and having an intermediate (HR: 1.34, 95% CI: 1.28-1.40) or high (HR: 1.37, 95% CI: 1.27-1.47) frailty score on admission had a higher risk of unplanned readmission. CHF patients with a mental disorder who have ≥3 other comorbidities and an intermediate frailty score had the highest probability of unplanned readmission (29.84%, 95% CI: 24.68-35.73%) after considering other patient-level factors and competing events. CHF patients who had a mental disorder diagnosis in the past 12months are more likely to be readmitted compared with those without a mental disorder diagnosis. CHF patients with frailty and a mental disorder have the highest probability of readmission. Addressing mental health care services in CHF patient's discharge plan could potentially assist reduce unplanned readmissions.

Trends in outpatient and inpatient visits for separate ambulatory-care-sensitive conditions during the first year of the COVID-19 pandemic: a province-based study.

The COVID-19 pandemic led to global disruptions in non-urgent health services, affecting health outcomes of individuals with ambulatory-care-sensitive conditions (ACSCs). We conducted a province-based study using Ontario health administrative data (Canada) to determine trends in outpatient visits and hospitalization rates (per 100,000 people) in the general adult population for seven ACSCs during the first pandemic year (March 2020-March 2021) compared to previous years (2016-2019), and how disruption in outpatient visits related to acute care use. ACSCs considered were chronic obstructive pulmonary disease (COPD), asthma, angina, congestive heart failure (CHF), hypertension, diabetes, and epilepsy. We used time series auto-regressive integrated moving-average models to compare observed versus projected rates. Following an initial reduction (March-May 2020) in all types of visits, primary care outpatient visits (combined in-person and virtual) returned to pre-pandemic levels for asthma, angina, hypertension, and diabetes, remained below pre-pandemic levels for COPD, and rose above pre-pandemic levels for CHF (104.8 vs. 96.4, 95% CI: 89.4-104.0) and epilepsy (29.6 vs. 24.7, 95% CI: 22.1-27.5) by the end of the first pandemic year. Specialty visits returned to pre-pandemic levels for COPD, angina, CHF, hypertension, and diabetes, but remained above pre-pandemic levels for asthma (95.4 vs. 79.5, 95% CI: 70.7-89.5) and epilepsy (53.3 vs. 45.6, 95% CI: 41.2-50.5), by the end of the year. Virtual visit rates increased for all ACSCs. Among ACSCs, reductions in hospitalizations were most pronounced for COPD and asthma. CHF-related hospitalizations also decreased, albeit to a lesser extent. For angina, hypertension, diabetes, and epilepsy, hospitalization rates reduced initially, but returned to pre-pandemic levels by the end of the year. This study demonstrated variation in outpatient visit trends for different ACSCs in the first pandemic year. No outpatient visit trends resulted in increased hospitalizations for any ACSC; however, reductions in rates of asthma, COPD, and CHF hospitalizations persisted.

Clinical and Socio Demographic Aspects of Congestive Heart Failure Patients

Background: Congestive heart failure (CHF) is a growing issue for healthcare systems throughout the developed world. Many factors have been linked to an increase in mortality in CHF patients. Despite heterogeneity in the research groups, several demographic and clinical variables appear to be consistently associated with a poor prognosis. Objective: To investigate the clinical and sociodemographic aspects of congestive heart failure patients. Materials and Methods: This study was a descriptive observational study conducted by the Department of Medicine at Narsingdi' 100- bed district hospital from July 2021 to June 2022. Purposive sampling was used to select 120 women and men with congestive heart failure from the cardiac center of 100-bed district hospital in Narsingdi, Bangladesh. Daily consecutive admissions were screened to identify eligible patients who arrived in the cardiac emergency room; Department of Cardiology required an admission diagnosis of congestive heart failure and was enrolled in this study on the basis of inclusion and exclusion criteria with a history of at least one well documented hospitalization for congestive heart failure. Results: Rhematic heart disease was identified in 38(31.7%), cardiomyopathy was found in 30(25.0%), hypertension was found in 21(17.5%), pericardial disease was found in 16(13.3%), and ischemaic heart disease was found in 3(2.5%). Factors related with congestive heart failure were 25 (20.8%) inadequate therapy, 25 (20.8%) arrhythmia, 23 (19.2%) respiratory, 17 (14.2%) anaemia, and 23 (19.2%) infective endocarditis. The majority of patients (75.5%) had NYHA class II, 38.7% had class III, and 5.8% had class IV. Conclusion: In conjunction with medical and demographic characteristics, major socio-environmental factors increased the likelihood of readmission due to congestive heart failure.

Impact of Clostridioides difficile infection in heart failure hospitalizations: analysis from the national inpatient sample database

Abstract Background Congestive heart failure (CHF) patients are at greater risk of nosocomial infections such as Clostridioides difficile infection (CDI) due to higher comorbidities, readmission rates, and prolonged hospital stays. Further, hypovolemia and sympathetic drive may aggravate myocardial dysfunction due to demand mismatch and worsen clinical outcomes. Purpose To assess the impact of CDI in congestive heart failure (CHF) hospitalizations nationally in the US. Methods The National Inpatient Sample database from 2016 to 2019 was queried to identify patients with a primary diagnosis of CHF. Subsequently, the sample was stratified based on the presence of CDI as a secondary diagnosis. The adjusted odds ratios (aOR) of in-hospital outcomes were calculated using chi-square statistics in software STAT v.17. Results Of 1,270,414 weighted hospitalizations with CHF, 8275 were diagnosed with CDI (0.65%). On adjusted analysis, patients with CHF and CDI had significantly higher in-hospital mortality (aOR 3.58, 95% CI 3.28-4.51, p&amp;lt;0.001), cardiac arrest (aOR 3.89, 95% CI 2.79-5.41, p&amp;lt;0.001), AMI (aOR 1.37, 95% CI 1.08-, p=0.007), MCS (aOR 5.16, 95% CI 3.91-6.8, p&amp;lt;0.001), stroke (aOR 1.85, 95% CI 1.09-3.14, p=0.022) and MACE (aOR 2.54, 95% CI 2.21-2.91, p&amp;lt;0.001), (Figure 1). Additionally, HF patients with CDI are associated with longer lengths of stay (12±16 vs. 5±6 ) and adjusted total charge ($133,045±291,290 vs. $51,919±133,303) compared to HF patients without CDI (Table 1). Conclusions CDI in CHF hospitalizations have adverse in-hospital outcomes with higher rates of in-hospital mortality, AMI, stroke, and MACE. This highlights the importance of early detection and aggressive infection prevention strategies in this high-risk population.Figure 1Table 1

Abstract 13086: National Trends in Timely Ambulatory Follow-Up After Acute Myocardial Infarction and Congestive Heart Failure Cospitalizations Among Medicare Beneficiaries

Introduction: Following hospitalization for acute myocardial infarction (AMI) or congestive heart failure (CHF), close outpatient follow-up is warranted for symptom monitoring and initiation or titration of evidence-based therapies. Objective: To describe temporal trends in ambulatory care following CHF and AMI hospitalizations, between 2010 and 2019. Methods: We examined a 100% sample of Medicare fee-for-service beneficiaries discharged to the community after an AMI or CHF hospitalization. We assessed quarterly rates of timely post-discharge cardiology and primary care follow-up, defined as receipt of an ambulatory visit within 14 days of discharge. We assessed trends for five subgroups based upon known disparities in cardiovascular outcomes: sex, race/ethnicity, Medicaid dual-eligibility, county-level social deprivation index, and rurality. Results: The AMI cohort included 1,680,916 hospitalizations (54.9% male, 9.4% Black, 81.7% White) and the CHF cohort included 4,256,405 hospitalizations (47.7% male, 16.2% Black, 75.0% White). Timely cardiology follow-up after AMI increased from 26.8% in 2010 to 39.4% in 2019 (absolute change 12.6%) while follow-up after CHF increased from 22.0% to 33.4% (absolute change 11.5%). The proportion of patients without cardiology or primary care follow-up after AMI decreased to 36.1% in 2019 and to 41.6% for CHF. Though rates of timely follow-up increased for all demographic groups, female, Black, Hispanic, Medicaid dual-eligible patients, patients residing in rural areas, and patients residing in counties with high social deprivation were less likely to receive follow-up throughout the study. Conclusions: Rates of timely ambulatory care after AMI and CHF hospitalization have improved, but the majority of patients do not receive follow-up within 14 days of discharge. Efforts to improve post-hospital cardiology and primary care follow-up have the potential to improve clinical outcomes and reduce disparities.

Abstract 12580: Impact of Zero Coronary Artery Calcium on Downstream Cardiac Testing

Introduction: While coronary artery calcium scoring (CAC) has emerged as a useful tool for cardiovascular disease (CVD) risk prediction, its impact on downstream resource use remains unclear, especially in those with zero CAC. The purpose of this study was to determine the relationship between zero CAC and downstream use of cardiac procedures. Methods: Consecutive CAC scores from two academic hospitals in Toronto, Canada, from 2011 - 2019, were linked to population-based databases. Subjects with zero calcium without previous CVD were subsequently propensity score-matched with a non-CAC-tested control group for age, sex, CVD risk factors and comorbidities relevant to receipt of testing. Downstream cardiac testing, myocardial infarction (MI), stroke, and congestive heart failure (CHF) hospitalizations were compared between the two groups. Results were analyzed using descriptive statistics and Cox proportional hazards regression models. Results: 4,884 patients (Mean 56.8y, SD 11.3) underwent CAC scoring, of whom 2,709 (55.5%) had zero CAC (Mean 52.9y, SD 10.6, 55.4% women). Compared to those not tested at 90 days, zero CAC subjects had similar graded exercise stress test (GXT) (72 tests vs 60, p = 0.29), stress echocardiography (40 vs 32, p = 0.34) and myocardial perfusion imaging (MPS) (26 vs 37, p = 0.15), but higher cardiac MRI (CMR) (48 vs 7, p &lt; 0.001) use. At 3.4 years, GXT (HR 1.24, 95% CI 1.14 - 1.35), stress echocardiography (HR 1.80, 95% CI 1.59 - 2.05) and CMR (HR 3.40, 95% CI 2.55 - 4.53) use was higher in the zero CAC group, whereas MPS (HR 1.08, 95% CI 0.97 - 1.21) and catheterization (HR 1.14, 95% CI 0.91 - 1.44) were similar and PCI (HR 0.59, 95% CI 0.35 - 0.98) and CABG (HR 0.14, 95% CI 0.03 - 0.61) were lower. There was an approximately 5-fold lower rate of MI (HR 0.22, 95% CI 0.10 - 0.51) in the zero CAC group at 3.4 years and no difference in stroke (HR 0.98, 95% CI 0.46 - 2.05) or CHF hospitalizations (HR 1.15, 95% CI 0.53 - 2.48). Conclusion: Zero CAC was associated with higher use of some non-invasive cardiac testing, similar use of catheterization, and reduced PCI, CABG and AMI when compared to a propensity score-matched control group. The results support the utility of a zero CAC in limiting invasive procedures while maintaining an association with reduced cardiac events.

Abstract 14338: The Impact of Medication-Assisted Treatment for Opioid Use Disorder on Congestive Heart Failure Outcomes

Introduction: Congestive heart failure (CHF) and opioid use disorder (OUD) are leading contributors to healthcare utilization in the United States. Little is known about how OUD treatment impacts clinical outcomes in patients with both CHF and OUD. We examined the impact of medication assisted treatment (MAT—buprenorphine and methadone) on outcomes for patients diagnosed with OUD and CHF, and which MAT medication is associated with the fewest cardiac toxicities. Hypothesis: The use of MAT in patients with both CHF and OUD will improve clinical outcomes related to CHF including hospitalizations, emergency room (ER) visits, and mortality. Methods: A retrospective cohort study of patients 18 years or older diagnosed with both CHF and OUD was conducted using Optum’s de-identified Clinformatics® Data Mart Database. Using a multivariate logistic regression model, patients who were prescribed MAT were compared to those who were not. The primary outcomes were CHF hospitalizations, CHF ER visits, all-cause hospitalizations, and mortality. Results: No significant differences in the primary outcomes between the MAT and non-MAT cohorts were observed. A subgroup analysis demonstrated that buprenorphine had a lower risk of mortality compared to methadone (HR 0.72, 95% CI 0.52-1.00, p=0.0482). Conclusions: No significant differences in CHF hospitalizations, CHF ER visits, and all-cause hospitalizations were observed between the MAT and non-MAT cohorts. Buprenorphine was associated with a lower risk of mortality when compared to methadone.

Abstract 12444: Pulse Pressure and Cardiovascular and Renal Outcomes by Age in the Chronic Renal Insufficiency Cohort

Pulse pressure (PP) is associated with cardiovascular events and the progression of chronic kidney disease (CKD) to end stage kidney disease (ESKD). While PP is known to widen with age, it is less clear what other clinical factors affect PP and whether the risks associated with wide PP are the same across all ages. We used Cox proportional hazards models to investigate the association of PP with development of 1) atherosclerotic cardiovascular disease (ASCVD) events (congestive heart failure hospitalization, myocardial infarction, stroke and peripheral artery disease) or death and 2) 50% reduction in estimated glomerular filtration rate (eGFR) or ESKD in the Chronic Renal Insufficiency Cohort (CRIC) Study. In sensitivity analyses, we evaluated the association of time-updated PP with these outcomes, accounting for potential time-updated confounders using inverse probability of treatment weighting. We evaluated for effect modification by age (divided into tertiles), apparent treatment-resistant hypertension (HTN), baseline diabetes mellitus (DM) status, baseline CKD stage and baseline cardiovascular disease (CVD). Among 5,621 participants with CKD followed for ~5.4 years, mean PP was 57±19 mmHg, 1,396 (25%) had an ASCVD event, 1,186 (21%) died and 1,783 (32%) participants experienced the composite renal outcome. Every 10 mm Hg wider PP was associated with 6% higher risk of an ASCVD event or death (time-updated adjusted hazard ratio [HR]=1.06, 95% CI 1.04, 1.08) and 17% higher risk of the composite renal outcome (time-updated adjusted HR=1.17, 95% CI 1.16, 1.18). Wider PP was associated with a higher risk of ASCVD events or death among participants in the lowest age tertile (21-61 years; Figure 1A ), but a higher risk of the composite renal outcome in the oldest age tertile (71-79 years; Figure 1B ), suggesting PP may be associated with different pathophysiology across ages.

Congestive Heart Failure in the Light of Ancient Wisdom of Unani Medicine: A Review

Congestive heart failure is a complex clinical syndrome that causes functional impairment of ventricular filling and ejection of blood. It can cause dyspnea, fatigue, and fluid retention, affecting exercise tolerance and causing pulmonary and peripheral edema. Moreover, it is a burgeoning and life-threatening syndrome characterized by significant morbidity and mortality, poor functional capacity and quality of life, and high costs. Worldwide congestive heart failure affects more than 64 million people. Nowadays: congestive heart failure is correlated with Suqūṭ-e-Qalb Imtilāʼī, by modern Unani physicians. However, the disease is mentioned in classical Unani literature under the headings of Ikhtilāj-e-qalbi (arrhythmia), Rabw (cardiac asthma), Buhr (cardiac asthma), Khafaqān (palpitation), Istisqā’ Laḥmī (anasarca), Du‘f al-Qalb (weakness of heart), Intiṣāb al-Nafas (orthopnoea), Sudda-e-Urooq-e-Qalb (coronary artery obstruction), Ghashī (syncope), Tasallub-al- Sharāyīn (arteriosclerosis) and Imtilā’ bi Hasbil Aw’iya (congestion of blood vessels). Congestive heart failure and mortality are on the rise despite the significant advancements in contemporary medicine and guidelines directed medical therapy for congestive heart failure. Congestive heart failure hospitalizations make up 1-2% of Western hospital admissions, with the highest 30-day readmission rate (20-25%) in congestive heart failure patients reflecting due to high comorbidity burden. Unani drugs, despite advancements in modern medicine, still significantly impact patient health. They are traditionally used for cardiac ailments like palpitations, coronary artery disease, heart weakness, and cardiotonic. Unani medicine especially Khamīrajat (fermented confections) used in various cardiac diseases is cardio-protective and cardiotonic. According to reports, complementary and alternative medicine is used by up to 61% of cardiac patients with coronary artery disease and those at risk for arteriosclerosis. Therefore, a thorough evaluation of the Unani literature on cardiac illness and its treatment in the Unani system of medicine is needed to decrease congestive heart failure social and economic burdens have become a major global public health priority. This review is an effort to summarize the Unani classical literature on congestive heart failure.

Association of mineral and bone biomarkers with adverse cardiovascular outcomes and mortality in the German Chronic Kidney Disease (GCKD) cohort

Mineral and bone disorder (MBD) in chronic kidney disease (CKD) is tightly linked to cardiovascular disease (CVD). In this study, we aimed to compare the prognostic value of nine MBD biomarkers to determine those associated best with adverse cardiovascular (CV) outcomes and mortality. In 5 217 participants of the German CKD (GCKD) study enrolled with an estimated glomerular filtration rate (eGFR) between 30–60 mL·min−1 per 1.73 m2 or overt proteinuria, serum osteoprotegerin (OPG), C-terminal fibroblast growth factor-23 (FGF23), intact parathyroid hormone (iPTH), bone alkaline phosphatase (BAP), cross-linked C-telopeptide of type 1 collagen (CTX1), procollagen 1 intact N-terminal propeptide (P1NP), phosphate, calcium, and 25-OH vitamin D were measured at baseline. Participants with missing values among these parameters (n = 971) were excluded, leaving a total of 4 246 participants for analysis. During a median follow-up of 6.5 years, 387 non-CV deaths, 173 CV deaths, 645 nonfatal major adverse CV events (MACEs) and 368 hospitalizations for congestive heart failure (CHF) were observed. OPG and FGF23 were associated with all outcomes, with the highest hazard ratios (HRs) for OPG. In the final Cox regression model, adjusted for CV risk factors, including kidney function and all other investigated biomarkers, each standard deviation increase in OPG was associated with non-CV death (HR 1.76, 95% CI: 1.35–2.30), CV death (HR 2.18, 95% CI: 1.50–3.16), MACE (HR 1.38, 95% CI: 1.12–1.71) and hospitalization for CHF (HR 2.05, 95% CI: 1.56–2.69). Out of the nine biomarkers examined, stratification based on serum OPG best identified the CKD patients who were at the highest risk for any adverse CV outcome and mortality.